Skip to content
August 08, 2022

Equity.Guru

Investment information for the new generation

PHRM.C

Revive Therapeutics (RVV.C) provided an update on their psilocybin development programs today. “Revive is building a specialty psilocybin-based product pipeline to treat mental illness, substance abuse and neurological disorders….
The psychedelics space is loaded with over-valued unicorns and also-rans, making it difficult for investors to find real growth opportunities. Here are some companies in the sector that have…
Looking at the charts of the Psychedelics sector, they can best be described as a mixed bag. Just like Cannabis, shroom stocks are taking a hit. This could just…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Whether you’re curious about taking a psychedelics investment trip or a tie-dyed-in-the-wool public market backer, psychedelics conferences are the best way to keep on top of industry advances and…
PharmaTher (PHRM.C) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS), also…
+326% wtf? PharmaTher (PHRM.C), the Vancouver-based psychedelics company is on an impressive run. In the last month, the stock has rocketed from $0.19 CAD up to $0.81 CAD, a…
Revive Therapeutics (RVV.C) advanced the December 21 deal with Newscope Capital (PHRM.C) past a binding LOI and into a purchase agreement to acquire psilocybin intellectual property from Newscope’s subsidiary,…